Search

Displaying results 3341 - 3350 of 10000 in total
  1. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.

  2. Drug

    Ergometrine

    go.drugbank.com/drugs/DB01253
    ApprovedInvestigational

    An ergot alkaloid with uterine and vascular smooth muscle contractile properties.

    Synonyms: D-lysergic acid-L-propanolamideProducts: Ergonovine Maleate Injection USP, 0.25mg/ml
  3. Drug

    Sulfisoxazole

    go.drugbank.com/drugs/DB00263
    ApprovedVet approved

    A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.

    Synonyms: N'-(3,4)Dimethylisoxazol-5-yl-sulphanilamideProducts: GANSOL %4 STERİL GÖZ DAMLASI, ÇÖZELTİ, 5 ML
  4. Drug

    Avacincaptad pegol

    go.drugbank.com/drugs/DB15165
    ApprovedInvestigational

    [L47696] AMD is the leading cause of vision loss in developed countries for people over 50 years old, with a global estimate of 170 million individuals affected. … Avacincaptad pegol is an RNA aptamer covalently bound to a branched polyethylene glycol (PEG) molecule.

  5. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    Desmoid tumors are typically characterized by aberrant activation in Notch signaling. … It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase

  6. Drug

    DAS-431 IV

    go.drugbank.com/drugs/DB05432
    Experimental

    DAS-431 IV is a dopamine D1 receptor agonist developed by DrugAbuse Sciences for the treatment of Addictions, Schizophrenia, Schizoaffective Disorders, Dementia, Parkinson's Disease, Strokes etc.

  7. Drug

    Talactoferrin alfa

    go.drugbank.com/drugs/DB05426
    Investigational

    Talactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. … It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.

  8. Drug

    Fluvoxamine

    go.drugbank.com/drugs/DB00176
    ApprovedInvestigational

    Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. … It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.

  9. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    [A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations. … It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.

    Synonyms: N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
  10. Drug

    Perhexiline

    go.drugbank.com/drugs/DB01074
    Approved

    Perhexiline is a coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.